Neuroendrocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic oncologists
- PMID: 28057354
- DOI: 10.1016/j.ygyno.2016.12.003
Neuroendrocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic oncologists
Abstract
Neuroendocrine tumors (NETs) are aggressive diseases developing from neuroendocrine cells that most frequently involve the gastro-entero-pancreatic tract and the lung, but more rarely are found in almost all body tissues. Limited biological and clinical data are currently available for NETs in uncommon sites, such as female genital tract. NETs represent 0.9% to 1.5% of the tumors of the uterine cervix. They are more likely to have lymph-vascular space invasion and lymph node involvement, and to develop local and distant relapses when compared with the mostly common cervical squamous cell carcinomas or adenocarcinomas. Positive immunostaining for synaptophysin, chromogranin, CD56, and neuron-specific enolase is often detected in cervical NETs . The most recent editions of the World Health Organization Classification of Gynecologic Tract tumors grouped cervical carcinoid tumor and atypical carcinoid tumor into low-grade NETs and cervical small cell neuroendocrine carcinoma and large cell neuroendocrine carcinoma into high-grade NETs. High-risk HPV DNA is detected in almost all cervical high-grade NETs. No treatment guidelines, based on prospective, well-designed clinical trials, are currently available due to the rarity of these tumors. Many authors have reported different multimodality approaches, mainly derived from NETs of the lung. These usually consist in radical hysterectomy followed by adjuvant chemotherapy or concurrent chemoradiation for early stage disease, definitive concurrent chemoradiation sometimes preceded by neoadjuvant chemotherapy and followed by adjuvant chemotherapy for locally advanced disease, and palliative chemotherapy for metastatic disease. In this systematic review, we address the histologic classification of cervical NETs, analyze their pathogenesis and overall prognosis, and evaluate the different treatment modalities described in the literature, in order to offer a possible algorithm that may help the clinicians in diagnosing and treating patients with these uncommon and aggressive malignancies.
Keywords: Cervical cancer; Chemotherapy; Neuroendocrine tumors.
Copyright © 2016 Elsevier Inc. All rights reserved.
Comment in
-
Neuroendocrine tumors of the cervix: an urgent call for joining forces.Int J Gynecol Cancer. 2019 Jul;29(6):985. doi: 10.1136/ijgc-2019-000631. Int J Gynecol Cancer. 2019. PMID: 31263020 No abstract available.
Similar articles
-
Updates and management algorithm for neuroendocrine tumors of the uterine cervix.Int J Gynecol Cancer. 2019 Jul;29(6):986-995. doi: 10.1136/ijgc-2019-000504. Int J Gynecol Cancer. 2019. PMID: 31263021
-
Spectrum of neuroendocrine carcinomas of the uterine cervix, including histopathologic features, terminology, immunohistochemical profile, and clinical outcomes in a series of 50 cases from a single institution in India.Ann Diagn Pathol. 2013 Feb;17(1):1-9. doi: 10.1016/j.anndiagpath.2012.01.009. Epub 2012 Apr 24. Ann Diagn Pathol. 2013. PMID: 22534245
-
Clinicopathologic features, incidence, and survival trends of gynecologic neuroendocrine tumors: a SEER database analysis.Am J Obstet Gynecol. 2019 Jul;221(1):53.e1-53.e6. doi: 10.1016/j.ajog.2019.02.052. Epub 2019 Mar 5. Am J Obstet Gynecol. 2019. PMID: 30849352
-
Treatment policy of neuroendocrine small cell cancer of the cervix.Eur J Gynaecol Oncol. 2004;25(1):40-4. Eur J Gynaecol Oncol. 2004. PMID: 15053060 Review.
-
Low-grade Neuroendocrine Tumor of the Cervix: Report of 3 Cases of a Rare Neoplasm With Review of the Literature.Int J Gynecol Pathol. 2022 Sep 1;41(5):437-446. doi: 10.1097/PGP.0000000000000851. Epub 2022 Jan 25. Int J Gynecol Pathol. 2022. PMID: 35075048 Free PMC article. Review.
Cited by
-
Advancements in the Understanding of Small-Cell Neuroendocrine Cervical Cancer: Where We Stand and What Lies Ahead.J Pers Med. 2024 Apr 27;14(5):462. doi: 10.3390/jpm14050462. J Pers Med. 2024. PMID: 38793044 Free PMC article. Review.
-
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.Proc Natl Acad Sci U S A. 2024 Apr 23;121(17):e2321898121. doi: 10.1073/pnas.2321898121. Epub 2024 Apr 16. Proc Natl Acad Sci U S A. 2024. PMID: 38625939
-
Prognostic model for survival in patients with neuroendocrine carcinomas of the cervix: SEER database analysis and a single-center retrospective study.PLoS One. 2024 Jan 5;19(1):e0296446. doi: 10.1371/journal.pone.0296446. eCollection 2024. PLoS One. 2024. PMID: 38181016 Free PMC article.
-
Competing risk nomogram and risk classification system for evaluating overall and cancer-specific survival in neuroendocrine carcinoma of the cervix: a population-based retrospective study.J Endocrinol Invest. 2024 Jun;47(6):1545-1557. doi: 10.1007/s40618-023-02261-7. Epub 2024 Jan 3. J Endocrinol Invest. 2024. PMID: 38170396 Free PMC article.
-
Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives.J Clin Med. 2023 Dec 15;12(24):7715. doi: 10.3390/jcm12247715. J Clin Med. 2023. PMID: 38137784 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials